Cell Therapy News/Articles, page-1955

Thanks Kenjii. I think this article highlights one of the problems with the announcement (IMO) - and perhaps why it ran up to 219% in inter day trade on the Nasdaq. It is unfortunate that the original data is being presented this way after the correction by JAMA. The 88% figure is of a small subset with know outcomes (death or discharge). 75% of the sample were still in hospital (and not necessarily on ventilators still - perhaps recovering) and their outcomes weren’t factored into the stats. Many more survivors may have been discharged. Some have said it is like for like as the mesoblast results were observed results over the same period - but let’s not forget that the outcomes for the M13 were being directly monitored - even if not discharged - which differs to the JAMA sample. It’s just one piece muddying the waters.